Insmed Incorporated (INSM) is a biopharmaceutical company — not an ETF — focused on serious and rare respiratory diseases. Roughly two dozen sell-side analysts cover the stock, and the consensus rating is a Strong Buy. The arithmetic mean of the verified 12-month targets is approximately $194, which rounds to a central target of $195. The individual targets range from about $158 (Mizuho) to roughly $243 (TD Cowen), a spread of nearly 2.5-to-1 that underscores how differently analysts model the launch trajectory and pipeline.
Recent activity skews positive but is not unanimous. In early November 2026, H.C. Wainwright initiated coverage with a Buy and a $220 target, Morgan Stanley reiterated Overweight at $213, Roth Capital lifted its target to $204, and Barclays and Guggenheim stood at $207 and $201, respectively. More cautious voices include Wolfe Research, which moved the stock to a Peer Perform rating, and several firms that trimmed targets after third-quarter results, including Guggenheim and Leerink Partners. The reasoning is broadly consistent: analysts see a large and expanding addressable market, but they differ sharply on how much of future peak sales should be priced in today.
Insmed shares closed near $123 in mid-November 2026, well below the 52-week high of $212.75. Moving to $195 would require an advance of roughly 59%, a very large move that implies not just continued commercial execution but also re-rating. The stock has been unusually volatile: it fell more than 40% over the past year even as the launch exceeded expectations, then rebounded roughly 20% in the weeks after third-quarter results. That combination of strong operating news and a weak share price reflects a market still deciding how much of the company's long-term peak-sales story to pay for up front.
BRINSUPRI (brensocatib), the first and only approved treatment for non-cystic fibrosis bronchiectasis (NCFB), is the core growth engine. It generated $400.1 million in third-quarter 2026 revenue, up 29% sequentially, and drove management to raise full-year guidance to $1.35–$1.40 billion. ARIKAYCE, used to treat Mycobacterium avium complex (MAC) lung disease, added $124.4 million, with a U.S. Food and Drug Administration (FDA) decision on a first-line label expansion expected by the PDUFA (Prescription Drug User Fee Act) date of January 28, 2027. Beyond these, the inhaled TPIP (treprostinil palmitil inhalation powder) program is advancing in Phase 3 across several large pulmonary indications. Management expects the company to reach cash-flow positivity in 2027, a milestone that could meaningfully support sentiment.
Insmed remains unprofitable: third-quarter EPS (earnings per share) came in at -$0.46, wider than the roughly -$0.39 consensus, because of heavy launch spending. With no meaningful P/E (price-to-earnings) ratio to lean on, investors must judge the shares on price-to-sales and enterprise value-to-sales, which sit around 13–14 times forward revenue — a demanding multiple for a company still burning cash. Other risks include potential label-expansion delays or setbacks, slower-than-expected BRINSUPRI uptake in Europe and Japan, the inherently binary nature of TPIP trial readouts, and the possibility of future equity issuance. Short interest of roughly 6% of the float also adds to volatility around news events.
The most durable reference points are the 52-week low near $90 and the 52-week high at $212.75. The stock's rebound from the low-$90s has carried it back through the $100 and $120 areas, which now act as support zones. On the upside, the prior high of $212.75 sits above the central target and represents a major resistance area, meaning the path to $195 would not require breaking to new all-time highs but would demand sustained buying through the low-to-mid $100s, a zone where the stock has repeatedly stalled.
Most analyst price targets reflect a roughly 12-month research horizon, though individual firms apply different assumptions about discount rates and peak sales. Key items to watch include the January 28, 2027 PDUFA decision on ARIKAYCE's first-line MAC indication, quarterly BRINSUPRI prescription and revenue trends, progress toward 2027 cash-flow positivity, TPIP Phase 3 enrollment and readouts, and any analyst target revisions following those events. Given the wide target range, changes in the dispersion of estimates may matter as much as the average itself.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening alone. For a company as news-sensitive as Insmed, an automated signal layer can help flag momentum changes between catalyst events.
The question of whether Insmed can reach $195 ultimately rests on whether the market decides to reward, rather than merely acknowledge, a genuine blockbuster launch. The central target of $195 — the average of analyst targets that range from about $158 to $243 — implies a very large, roughly 59% move from the current price near $123. The bull case is anchored in rapid BRINSUPRI growth, a near-term ARIKAYCE catalyst, and a broad TPIP pipeline, while the bear case centers on ongoing losses, a rich sales multiple, and unusually wide disagreement among analysts. Investors should watch commercial execution and the January 2027 regulatory decision more closely than any single price target, and no target should be treated as a guarantee of future performance.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, INSM has been closely correlated with CNTN. These tickers have moved in lockstep 74% of the time. This A.I.-generated data suggests there is a high statistical probability that if INSM jumps, then CNTN could also see price increases.
| Ticker / NAME | Correlation To INSM | 1D Price Change % | ||
|---|---|---|---|---|
| INSM | 100% | -1.69% | ||
| CNTN - INSM | 74% Closely correlated | -5.99% | ||
| ENGN - INSM | 42% Loosely correlated | +7.56% | ||
| TRDA - INSM | 41% Loosely correlated | +1.41% | ||
| AXON - INSM | 40% Loosely correlated | +0.70% | ||
| ARRY - INSM | 40% Loosely correlated | +1.20% | ||
More | ||||